NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00115700,Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma,https://clinicaltrials.gov/study/NCT00115700,,COMPLETED,Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy (involved field radiotherapy) and investigational therapy (involved field radiotherapy and chemotherapy plus rituximab). The main endpoint is progression free survival but overall survival and the influence of t(14;18) status will also be studied.,NO,Follicular Lymphoma,DRUG: Cyclophosphamide|RADIATION: Radiotherapy|DRUG: Vincristine|DRUG: Prednisolone|DRUG: Rituximab,"Progression Free Survival (PFS). Period from the date of randomisation to 1st progression of disease or death from any cause., Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual. Long term follow-up analysis is planned after 10 years of follow-up","Pre- and post-treatment prevalence of the t(14;18) translocation, in peripheral blood and bone marrow between arms, Peripheral blood at commencement of treatment, after 1 year and upon relapse is collected and stored for later analysis to be done as part of translational studies when funding becomes available|Overall Survival (OS), Period from date of randomisation to date of death from any cause., Main analysis will be done on completion of 5 years follow-up after the end of accrual. An interim analysis to be done after at least 3 years of follow-up. A futility analysis will be performed after the 5 year analysis. In the absence of futility being|Location of first relapse, Period from date of randomisation to date of first relapse location via CT scan and or other imaging as required, Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual|To compare time to evolution to higher histological grade, Period from date of randomisation to date of higher histological grade via CT scan and or other imaging as required, Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual|Freedom from progression., Period from date of randomisation to date of first disease progression., Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual. Long term follow-up analysis is planned after 10 years of follow-up|Acute and late toxicities and secondary malignances, Frame after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual",,Trans Tasman Radiation Oncology Group,Australasian Leukaemia and Lymphoma Group,ALL,"ADULT, OLDER_ADULT",PHASE3,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,TROG 99.03|ALLG NHLLOW5,2000-02,2018-08,2018-08,2005-06-24,,2022-11-18,"The Canberra Hospital, Garran, Australian Capital Territory, 2605, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, 2298, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Westmead Hospital, Wentworthville, New South Wales, 2145, Australia|Albury Base/Murray Valley Private Hospital, West Albury, New South Wales, 2640, Australia|Illawarra Cancer Care Centre, Wollongong, New South Wales, 2500, Australia|Radiation Oncology - Mater Centre, South Brisbane, Queensland, 4101, Australia|Genesis Cancer Care (previously Premion), Tugun, Queensland, 4224, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, 5011, Australia|Launceston General Hospital, Launceston, Tasmania, 7250, Australia|St John of God Hospital, Ballarat, Victoria, 3350, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3002, Australia|Andrew Love Cancer Care Centre, Geelong Hospital, Geelong, Victoria, 3220, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Princess Margaret Hospital, Toronto, Canada|Auckland Hospital, Auckland, 1001, New Zealand|Waikato Hospital, Hamilton, 3200, New Zealand|Wellington Hospital, Wellington, 7902, New Zealand",
